Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS)
Casasanta N, Patel R, Raymond S, Kier M, Blanter J, Sohval S, Hovstadius M, Wu C, Zimmerman B, Cascetta K, Bagiella E, Tiersten A. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS). Clinical Breast Cancer 2024, 24: 585-596. PMID: 38971641, DOI: 10.1016/j.clbc.2024.06.005.Peer-Reviewed Original ResearchBreast Cancer IndexEarly-stage breast cancerOncotype DX RSAssociated with discordanceOncotype DX recurrence scoreAdjuvant therapy benefitReview of womenOncotype DXRecurrence scoreRecurrence riskEndocrine therapyCancer indexRetrospective chart review of womenChart review of womenRetrospective review of womenRisk of distant recurrenceTherapy benefitRisk of recurrenceRetrospective chart reviewRegression modelsUnivariate logistic regression modelLogistic regression modelsPrediction scoreDistant recurrenceAdjuvant therapyFactors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer.
Yang A, Baldwin E, Casasanta N, Tiersten A, Kier M. Factors that impact aromatase inhibitor adherence in early-stage hormone receptor positive breast cancer. Journal Of Clinical Oncology 2024, 42: e12524-e12524. DOI: 10.1200/jco.2024.42.16_suppl.e12524.Peer-Reviewed Original ResearchFirst-line AITherapy useSide effectsRecurrence riskBreast cancerNo significant differenceAromatase inhibitorsEarly-stage hormone receptor-positive breast cancerHormone receptor-positive breast cancerEfficacy of aromatase inhibitorsTreatment due to side effectsReceptor-positive breast cancerAI adherenceEarly-stage breast cancerSocioeconomic demographicsPatients' recurrence riskCohort median agePositive breast cancerSignificant differenceFisher's exact testSide effect frequencyPearson chi-square testKruskal-Wallis rank sum testRank sum testEndocrine treatment